RALLYBIO CORP (RLYB)

US75120L1008 - Common Stock

1.59  +0.12 (+8.16%)

After market: 1.59 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

RALLYBIO CORP

NASDAQ:RLYB (3/27/2024, 8:00:01 PM)

After market: 1.59 0 (0%)

1.59

+0.12 (+8.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap60.09M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RLYB Daily chart

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 44 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.

Company Info

RALLYBIO CORP

234 Church Street, Suite 1020

New Haven CONNECTICUT

P: 12038593820

CEO: Martin W. Mackay

Employees: 44

Website: https://rallybio.com/

RLYB News

News Image16 days ago - Rallybio CorporationRallybio Reports Fourth Quarter and Full Year 2023 Financial Results
News Imagea month ago - Rallybio CorporationRallybio to Present at the TD Cowen 44th Annual Health Care Conference
News Image2 months ago - Seeking AlphaJefferies cuts Rallybio to hold, cites lack of near-term catalysts (NASDAQ:RLYB)

Jefferies has downgraded Rallybio (RLYB) to hold, citing a lack of near-term pipeline catalysts and slow development of its lead drug program.

News Image2 months ago - Seeking AlphaRallybio shares jump 13% on restructuring, cash runway extension (NASDAQ:RLYB)

Rallybio (RLYB) shares rose 13% early Tuesday after the company announced it was cutting 45% of its workforce to streamline its drug portfolio and extend its ca

News Image2 months ago - Rallybio CorporationRallybio Announces Portfolio Prioritization and Provides Corporate Update
News Image3 months ago - Rallybio CorporationRallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

RLYB Twits

Here you can normally see the latest stock twits on RLYB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example